Skip to main content

CGMs available on prescription from August 2022

Anyone with type 1 diabetes can now access real-time continuous glucose monitoring (CGM) through their GP or local hospital. Once prescribed, repeat prescriptions can be collected from local pharmacies.
JDRF logo placeholder for author profile picture
Mary-Liz McGrath 2 August 2022

A young woman wearing a continuous glucose monitor

Anyone with type 1 diabetes can now access real-time continuous glucose monitoring (CGM) through their GP or local hospital. Once prescribed, repeat prescriptions can be collected from local pharmacies.

The Dexcom ONE Real Time-Continuous Glucose Monitoring can now be prescribed on the NHS, across all four nations of the UK. This will help put into action the recently updated NICE guidelines in England and Wales on blood glucose monitoring, which say that anyone with type 1 should be offered CGM or flash glucose monitoring as part of standard care.

Patients will be provided with a sensor, transmitter and information on how to use it. The Dexcom ONE has much of the same functions as the G6 device, except for sharing and looping capabilities. Read the differences between the Dexcom devices.

What are CGMs and how can they help people with type 1?

CGMs use a sensor attached to the body which transmits real-time information on glucose levels to a handset or the user’s mobile phone, allowing them to check their glucose levels more often and without the need for painful finger prick tests.

CGMs also alert the user when glucose levels become too low or too high, meaning they are better able to avoid dangerous hypoglycaemia (hypos) or hyperglycaemia (hypers) which can potentially cause long-term complications. They also allow the user to review their glucose trends over time, rather than just giving a snapshot of when the test is taken, as is the case with finger prick tests.

Our work with tech partners

We’ve been working with partners like Dexcom and organisations like NICE and NHS England to help bring about this sort of change for people with type 1.

Our Senior Technology Access Specialist, Lesley Jordan, says: “This is a major breakthrough in the treatment of type 1 diabetes which should allow everyone with type 1 access to this life changing technology. JDRF will work with local decision makers and people with type 1 diabetes to ensure equitable access to glucose monitoring technology as recommended by NICE.”

What do you need to do now?

Whilst this device is now available to be prescribed on the NHS, it may take some time to be rolled out in all areas across the UK. People with type 1 should ask their clinician at their next appointment if it is available in their area, and if not, when it will be.

Read more
A row of vials of clear liquid with black lids. A blue gloved hand is pinching the top of the closest vial as if to pick it up.
13 May 2024

Novel insulin being developed to enable implantable insulin pumps

Medtronic Diabetes have announced they are funding the biopharmaceutical company Arecor Therapeutics to develop a novel, highly concentrated, thermostable insulin, which will be specialised for use in implantable insulin pumps.

Read more
Professor Colin Dayan at Cardiff University, working on immunotherapy for type 1 diabetes cure research
Research
18 April 2024

Professor Colin Dayan presented with the 2023 JDRF Rumbough Award 

The award recognises Professor Dayan’s remarkable accomplishments in type 1 diabetes research.

Read more
Two young children sat on the floor hugging each other.
18 April 2024

Genetically unique siblings reveal new treatment target for type 1 diabetes

Two siblings who have unique changes in a key gene have given researchers new insights that could help lead to innovative new treatments in type 1 diabetes.

Read more
A female doctor works at a laptop on a table. She is wearing a shirt and glasses with a stethoscope around her neck.
17 April 2024

New international medical code launches for presymptomatic type 1 diabetes

JDRF-funded researchers from the University of Birmingham have joined forces with NHS England to develop a diagnostic code for use on electronic medical records of people in the earliest stages of type 1 diabetes, allowing them to receive better, more timely healthcare and access to emerging treatments.